| Title |
Localization and upregulation of survivin in cancer health disparities: a clinical perspective
|
|---|---|
| Published in |
Biologics: Targets & Therapy, July 2015
|
| DOI | 10.2147/btt.s83864 |
| Pubmed ID | |
| Authors |
Salma Khan, Heather Ferguson Bennit, Malyn May Asuncion Valenzuela, David Turay, Carlos J Diaz Osterman, Ron B Moyron, Grace E Esebanmen, Arjun Ashok, Nathan R Wall |
| Abstract |
Survivin is one of the most important members of the inhibitors of apoptosis protein family, as it is expressed in most human cancers but is absent in normal, differentiated tissues. Lending to its importance, survivin has proven associations with apoptosis and cell cycle control, and has more recently been shown to modulate the tumor microenvironment and immune evasion as a result of its extracellular localization. Upregulation of survivin has been found in many cancers including breast, prostate, pancreatic, and hematological malignancies, and it may prove to be associated with the advanced presentation, poorer prognosis, and lower survival rates observed in ethnically diverse populations. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Canada | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 62 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 62 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 15 | 24% |
| Student > Master | 9 | 15% |
| Student > Bachelor | 6 | 10% |
| Researcher | 6 | 10% |
| Professor > Associate Professor | 3 | 5% |
| Other | 8 | 13% |
| Unknown | 15 | 24% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 17 | 27% |
| Medicine and Dentistry | 10 | 16% |
| Agricultural and Biological Sciences | 8 | 13% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 5% |
| Social Sciences | 3 | 5% |
| Other | 3 | 5% |
| Unknown | 18 | 29% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 July 2015.
All research outputs
#19,945,185
of 25,374,917 outputs
Outputs from Biologics: Targets & Therapy
#214
of 284 outputs
Outputs of similar age
#189,301
of 277,613 outputs
Outputs of similar age from Biologics: Targets & Therapy
#3
of 4 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. This one is in the 18th percentile – i.e., 18% of other outputs scored the same or lower than it.
So far Altmetric has tracked 284 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.2. This one is in the 21st percentile – i.e., 21% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 277,613 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 26th percentile – i.e., 26% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 4 others from the same source and published within six weeks on either side of this one.